Replies to post #349591 on Innovation Pharmaceuticals Inc (IPIX)

[Here Today]

Straight from the PR:

“After an interim review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days.”

So the only reason the DMC would look to extend from 3 days of Brilacidin treatment to 5 days of treatment would be because of positive developments they are seeing in those first 3 days of treatment. Some keys to the trial would be to see how quick patients get off of ventilators, how well the lung function/inflammation reduced and healing was progressing from just the 3 days of treatment.